Latest Insider Transactions at Synaptogenix, Inc. (SNPX)
This section provides a real-time view of insider transactions for Synaptogenix, Inc. (SNPX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Synaptogenix, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Synaptogenix, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Alan J Tuchman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,726
-30.63%
|
$12,082
$7.85 P/Share
|
|
Jun 30
2025
|
Alan J Tuchman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,315
+43.37%
|
-
|
|
Jun 30
2025
|
Bruce Bernstein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,863
-38.29%
|
$69,041
$7.85 P/Share
|
|
Jun 30
2025
|
Bruce Bernstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,657
+48.91%
|
-
|
|
Jun 30
2025
|
Jonathan Schechter Director |
SELL
Payment of exercise price or tax liability
|
Direct |
8,630
-38.08%
|
$60,410
$7.85 P/Share
|
|
Jun 30
2025
|
Jonathan Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,575
+48.77%
|
-
|
|
Jun 30
2025
|
Joshua Silverman Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
16,768
-38.59%
|
$117,376
$7.85 P/Share
|
|
Jun 30
2025
|
Joshua Silverman Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
41,919
+49.1%
|
-
|
|
Jun 30
2025
|
Robert Weinstein Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,164
-36.83%
|
$43,148
$7.85 P/Share
|
|
Jun 30
2025
|
Robert Weinstein Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,410
+47.93%
|
-
|
|
Jun 30
2025
|
William S. Singer Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,164
-36.84%
|
$43,148
$7.85 P/Share
|
|
Jun 30
2025
|
William S. Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,410
+47.95%
|
-
|
|
Dec 16
2022
|
Alan J Tuchman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
27,000
-45.0%
|
$27,000
$1.17 P/Share
|
|
Dec 16
2022
|
Bruce Bernstein Director |
SELL
Open market or private sale
|
Direct |
22,500
-44.93%
|
$22,500
$1.17 P/Share
|
|
Dec 16
2022
|
Daniel L. Alkon President and CSO |
SELL
Open market or private sale
|
Direct |
19,688
-35.64%
|
$19,688
$1.17 P/Share
|
|
Dec 16
2022
|
Jonathan Schechter Director |
SELL
Open market or private sale
|
Direct |
20,250
-41.54%
|
$20,250
$1.17 P/Share
|
|
Dec 16
2022
|
Joshua Silverman Executive Chairman |
SELL
Open market or private sale
|
Direct |
19,012
-33.21%
|
$19,012
$1.17 P/Share
|
|
Dec 16
2022
|
Robert Weinstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,000
-44.85%
|
$27,000
$1.17 P/Share
|
|
Dec 16
2022
|
William S. Singer Director |
SELL
Open market or private sale
|
Direct |
27,000
-45.0%
|
$27,000
$1.17 P/Share
|
|
Jul 13
2021
|
Joshua Silverman Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+46.15%
|
-
|
|
Jul 13
2021
|
Daniel L. Alkon President and CSO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+46.65%
|
-
|
|
Jul 13
2021
|
Bruce Bernstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.96%
|
-
|
|
Jul 13
2021
|
Robert Weinstein Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+49.92%
|
-
|
|
Jul 13
2021
|
Jonathan Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+48.0%
|
-
|
|
Jul 13
2021
|
George Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Jul 13
2021
|
William S. Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Jul 13
2021
|
Alan J Tuchman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Jun 14
2021
|
Joshua Silverman Executive Chairman |
BUY
Open market or private purchase
|
Direct |
10,000
+40.0%
|
$80,000
$8.3 P/Share
|
|
Jun 14
2021
|
Daniel L. Alkon President and CSO |
BUY
Open market or private purchase
|
Direct |
10,000
+46.55%
|
$80,000
$8.26 P/Share
|